The current clinical value of the DCIS Score

Area of Science:

• Oncology
• Genomics
• Breast Cancer Research

Background:

• Ductal carcinoma in situ (DCIS) diagnosis is increasing due to mammographic screening.
• Current DCIS management often involves surgery and radiation, but omitting radiation is possible for low-risk patients.
• Predicting recurrence risk in DCIS is challenging due to limitations of current clinicopathologic features.

Framework:

• Molecular profiling offers a novel approach to assess individual tumor biology and recurrence risk.
• The DCIS Score is a 12-gene assay designed to evaluate local failure risk in DCIS patients post-excision.
• This assay provides risk stratification independent of traditional clinicopathologic markers.

Implementation:

• Expert breast surgeons and radiation oncologists convened to discuss DCIS management controversies.
• The potential value of the DCIS Score in clinical practice was evaluated.
• The discussion focused on integrating molecular data into treatment planning for DCIS.

Implications:

• The DCIS Score provides clinically relevant, personalized risk information for DCIS patients.
• This molecular assay can enhance patient-physician discussions and shared decision-making.
• Personalized risk assessment may lead to more tailored treatment strategies for DCIS, potentially optimizing outcomes and reducing overtreatment.